B Cell Lymphoma Unclassifiable With Features Intermediate Between Diffuse Large B Cell Lymphoma And Classical Hodgkin Ly C1333878
A rare blood cancer with features overlapping two different lymphoma types, making it difficult to classify. This aggressive condition typically affects adults and requires specialized treatment approaches.
Key facts at a glance
- ICD-10
- C80.1
- ICD-11
- 2A00.0
- Body system
- oncologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Rapidly enlarging lymph node
Generalized symptoms
(oncologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
B symptoms (fever, night sweats, weight loss)
(oncologic)Constitutional fatigue
(oncologic)Extranodal involvement (e.g., skin lesions)
(oncologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Intensive Chemoimmunotherapy
Aggressive combination chemotherapy with rituximab (R-EPOCH or similar regimens) is the primary approach for this borderline lymphoma. Treatment intensity often exceeds standard DLBCL protocols.
Targeted drug therapy with dose adjustment
Active treatment with regular monitoring by a healthcare provider is recommended.
Additional treatment options
Salvage Immunochemotherapy
Second-line chemotherapy with immunotherapy for disease that does not respond to initial treatment or relapses. Typically involves different drug combinations to overcome resistance.
medicationConsolidation with Stem Cell Transplant
High-dose chemotherapy with autologous or allogeneic stem cell rescue following remission induction. Allogeneic transplant may offer graft-versus-lymphoma effect.
procedureCAR-T Cell Therapy
Chimeric antigen receptor T-cell therapy targeting CD19 is an emerging option for relapsed/refractory disease. Patient's T-cells are modified to recognize and attack lymphoma cells.
medicationResponse Assessment and Surveillance
Regular PET-CT imaging and biopsies to assess treatment response and detect early relapse. Follow-up frequency typically decreases over time but continues for years.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is B Cell Lymphoma Unclassifiable With Features Intermediate Between Diffuse Large B Cell Lymphoma And Classical Hodgkin Ly C1333878?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2017.
Grant C, Wilson WH, Dunleavy K. B-cell lymphoma unclassifiable with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma. Expert Rev Hematol. 2014;7(5):599-612.
Wilson WH, Pittaluga S, Nicolae A, et al. A prospective study of mediastinal gray-zone lymphoma. Blood. 2014;124(10):1563-1569.
Martinez-Mateu A, Botta L, Chopra N, et al. Treatment outcomes in gray-zone lymphoma: a systematic review and meta-analysis. Lancet Haematol. 2020;7(8):e599-e610.
Medication Comparisons
Compare medications used to treat B Cell Lymphoma Unclassifiable With Features Intermediate Between Diffuse Large B Cell Lymphoma And Classical Hodgkin Ly C1333878. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy